Short answer
AbbVie Inc (ABBV) filed its Q3 2025 10-Q quarterly report on Nov 4, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $15.8B (up 9.1% year over year) with net income of $186M.
Q3 2025 key financials · XBRL
- Revenue
- $15.8B
- +9.1% YoY · +2.3% QoQ
- Net income
- $186M
- −88.1% YoY · −80.2% QoQ
- Operating margin
- 12.1%
- EPS (diluted)
- $0.10
- −88.6% YoY · −80.8% QoQ
Source: XBRL data from the AbbVie Inc (ABBV) Q3 2025 10-Q on SEC EDGAR. USD.
AbbVie Inc Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $15.8B Q3 2025, up 9.1% vs $14.5B Q3 2024; Nine months $44.5B, up 8.0% vs $41.2B prior year
- Gross margin approx. 66.4% Q3 2025 vs ~70.9% Q3 2024 (calc. from $10.47B/$15.78B vs $10.25B/$14.46B), decline due to $847M intangible impairments
- Best performing segment: Skyrizi Immunology revenues up 46.8% Q3 and 58.1% YTD; Worst: Humira down 55.4% Q3 and 55.0% YTD from biosimilar competition
- Operating cash flow $13.8B for nine months, up $2.1B YoY; capital expenditures $885M in 2025 vs $683M prior year; repurchased 3M shares for $606M
- Management expects regulatory approvals and clinical data readouts; notes pricing pressures from U.S. MFN pricing order and global trade risks; increased dividend 5.5% to $1.73/share starting Q1 2026
Risk Factors
- Section 'risk_factors' was empty or not found.
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other AbbVie Inc quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.